379 related articles for article (PubMed ID: 27821505)
1. Mechanistic approaches for the prevention and treatment of chronic GVHD.
Cutler CS; Koreth J; Ritz J
Blood; 2017 Jan; 129(1):22-29. PubMed ID: 27821505
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host disease management.
Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. Thinking out of the box--new approaches to controlling GVHD.
Baron F; Humblet-Baron S; Ehx G; Servais S; Hannon M; Belle L; Lechanteur C; Briquet A; Giet O; Baudoux E; Willems E; Beguin Y
Curr Hematol Malig Rep; 2014 Mar; 9(1):73-84. PubMed ID: 24390548
[TBL] [Abstract][Full Text] [Related]
6. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
Weitz M; Strahm B; Meerpohl JJ; Bassler D
Cochrane Database Syst Rev; 2014 Feb; (2):CD009898. PubMed ID: 24569961
[TBL] [Abstract][Full Text] [Related]
8. Current and future approaches for control of graft-versus-host disease.
Koreth J; Antin JH
Expert Rev Hematol; 2008 Oct; 1(1):111. PubMed ID: 20151032
[TBL] [Abstract][Full Text] [Related]
9. Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.
Rozmus J
Front Immunol; 2020; 11():574569. PubMed ID: 33613511
[TBL] [Abstract][Full Text] [Related]
10. Established and Emerging Treatments of Skin GvHD.
Link-Rachner CS; Sockel K; Schuetz C
Front Immunol; 2022; 13():838494. PubMed ID: 35185931
[TBL] [Abstract][Full Text] [Related]
11. [Graft-versus-host disease: current understanding of immune pathogenesis and clinical treatment].
Matsuoka KI
Rinsho Ketsueki; 2021; 62(8):1281-1287. PubMed ID: 34497217
[TBL] [Abstract][Full Text] [Related]
12. Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease.
Michael M; Shimoni A; Nagler A
Acta Haematol; 2013; 130(1):34-43. PubMed ID: 23392110
[TBL] [Abstract][Full Text] [Related]
13. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
Hamilton BK
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):228-235. PubMed ID: 30504315
[TBL] [Abstract][Full Text] [Related]
14. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
15. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
16. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
17. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
19. Advances in graft-versus-host disease biology and therapy.
Blazar BR; Murphy WJ; Abedi M
Nat Rev Immunol; 2012 May; 12(6):443-58. PubMed ID: 22576252
[TBL] [Abstract][Full Text] [Related]
20. New strategies in the treatment of graft-versus-host disease.
Basara N; Blau IW; Willenbacher W; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S12-5. PubMed ID: 10933179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
